Coherus BioSciences (CHRS) Reports Q3 Loss Per Share of $1.86
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.50 +1.35%
Revenue Growth %: +40.6%
Financial Fact:
Diluted net income/(loss) per share: 0.15
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +40.6%
Financial Fact:
Diluted net income/(loss) per share: 0.15
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.86), versus ($1.79) reported last year. Revenue for the quarter came in at $7.2 million, versus $16.1 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral
- KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
